MSD and syndex reach cooperation on "breakthrough" cancer compound drugs

Source: will the combination of two breakthrough cancer drugs of Ding Xiangyuan 2015-04-07 be better than one drug? In a phase 1B / 2 study, drug giant MSD and syndax of Waltham, Massachusetts plan to use keysruda, a MSD blockbuster anti-PD-1 treatment drug, in combination with entinostat, a small biotech company, to treat non-small cell lung cancer or melanoma Researchers plan to start recruiting for the study in the second half of this year Syndax is one of the few biotech companies to qualify for breakthrough drugs for cancer drugs The company joined the first wave of breakthrough drugs back in 2013, when it won the breakthrough drug qualification for its HDAC inhibitor, entenole Currently, the drug is in the process of 3 The phase test was used to treat postmenopausal women with metastatic ER positive breast cancer FDA released the breakthrough drug qualification after reviewing excellent progression free and total survival data obtained in phase 2 trials, which could provide a potentially shorter route for drug approval Prior to this cooperation, MSD has signed a series of agreements, and the company believes that its PD-1 drugs can be combined with a wide range of targeted drugs naturally Keytruda works by removing the natural camouflage that cancer cells use to evade the immune system Bristol Myers Squibb is a leader in this field, followed by MSD, whose opdivo has recently been approved for lung cancer treatment